ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 907

Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis

Hilde B. Hammer1 and Tore K. Kvien2, 1Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologics, longitudinal studies, Rheumatoid arthritis (RA), synovitis and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Ultrasound (US) is sensitive for detecting tenosynovitis in patients with rheumatoid arthritis (RA), where the synovitis can be assessed by grey scale (GS) and the increased vascularization by power Doppler (PD). The extensor carpi radialis (ECU) tendon in the wrist and the tibialis posterior (TP) tendon in the ankle are frequently involved in RA patients, and the tenosynovitis can be scored by use of a semi-quantitative (0-3) scoring system. The objective of the present study was to assess the involvement of ECU and TP tendons in patients with established RA as well as to explore the change in US scores of these tendons during treatment with biologic disease-modifying anti-rheumatic drugs (bDMARDs).

Methods:

A total of 181 RA patients (83% women, mean (SD) age 51 (13) years, disease duration 11 (9) years, 77 % positive for anti-CCP) were examined when they started bDMARD (infliximab 10%, etanercept 43%, adalimumab 8%, golimumab 5%, certolizumab pegol 5%, rituximab 19%, abatacept 4% and tocilizumab 6%). All were examined at baseline and after 1, 2 and 3 months with US (GS and PD of ECU and TP tendons bilaterally, all assessments performed by one sonographer (HBH) with Siemens Acuson Antares, Excellence version, using a 5–13 MHz probe with an optimized pre-setting of the machine for all examinations), laboratory and clinical assessments. The changes from baseline were assessed by use of paired samples T-test.

Results:

Tenosynovitis was found in a high number of tendons at baseline (table). The mean (SD) sum score of the four tendons was 2.7 (2.7) for GS and 1.6 (2.2) for PD, including 26% of the patients with no GS inflammation and 51% with no PD activity in any tendon. Mean (SD) baseline values for the clinical examinations were: ESR 28.6 (21.7), CRP 14.2 (20.6) and DAS28 4.6 (1.5). Both sum scores GS and PD decreased significantly from baseline to 1 month (p<0.001 and p=0.013, respectively), and both showed highly significant reduction after 3 months (p<0.001) (figure). Also ESR, CRP and DAS28 decreased already after 1 month (p<0.001 for all), as well as after 3 months (p<0.001 for all).

Conclusion:

A large number of ECU and TP tendons were inflamed at baseline, and the sum scores of both GS and PD fell significantly already after 1 month. Since tenosynovitis in ECU and TP tendons are common in RA patients and responsive to change during bDMARD treatment, US of these tendons should be considered as candidates for inclusion in future US scores of RA patients.

 

 

 

ECU tendons

TP tendons

 

Grey scale (percentage involvement)

Power Doppler (percentage involvement)

Grey scale (percentage involvement)

Power Doppler (percentage involvement)

Score 0

57

76

64

76

Score 1

21

11

15

9

Score 2

17

11

14

11

Score 3

5

2

7

4

 

 

 

 

 

 

 

 


Disclosure:

H. B. Hammer,
None;

T. K. Kvien,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasonographic-tenosynovitis-score-is-responsive-to-biologic-treatment-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology